THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 100 participants.

Also called NCT02732704

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02732704
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Germany, Netherlands (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT02732704. Allocation not applicable; no masking; primary purpose treatment. Start 2018-04-20 (actual); primary completion 2022-08-29 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
THE ALIGN-AR EFS TRIAL: JenaValve Pericardial TAVR Aortic Regurgitation Study
Condition
Aortic Regurgitation
Intervention (Device)
JenaValve Pericardial TAVR System
Lead sponsor
JenaValve Technology, Inc. (class: industry)

Record details

Record id
cardio:ct-nct02732704
Content hash
56f97fc2a0b0238d9fd33a7512772d930545d9ca6f40066350af189e84eadd8c